methyl ethyl fumaric acid ester | 4749-70-6

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl ethyl fumaric acid ester
• 英文别名: ethyl methyl fumarate；methyl ethyl fumarate；diethyl fumarate；EMF；fumaric acid methyl ethyl ester；Ethyl-methyl-fumarat；4-O-ethyl 1-O-methyl (E)-but-2-enedioate
• CAS: 4749-70-6
• 化学式: C₇H₁₀O₄
• 分子量: 158.154
• InChiKey: JDOZUYVDIAKODH-SNAWJCMRSA-N

物化性质

• 沸点：
  40-41 °C(Press: 0.01 Torr)
• 密度：
  1.0717 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl ethyl fumaric acid ester 在 三氟甲磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 生成 (2R,3S)-2-ethyl 3-methyl 1-((R)-1-phenylethyl)aziridine-2,3-dicarboxylate
  参考文献：
  名称：

  Origins of Selectivity in Brønsted Acid-Promoted Diazoalkane−Azomethine Reactions (The Aza-Darzens Aziridine Synthesis)

  摘要：

  The mechanism of the Bronsted acid-catalyzed aza-Darzens reaction is explored by charting the stereochemical outcome of the triflic acid-promoted conversion of trans-triazolines to cis-aziridines. These experiments are consistent with the intermediacy of an alpha-diazonium-beta-amino ester intermediate.

  DOI：

  10.1021/ol200313m
• 作为产物：
  描述：

  methyl (E)-4-chloro-4-oxo-2-butenoate 、 乙醇 以84%的产率得到
  参考文献：
  名称：

  DYMICKY, M., ORG. PREP. AND PROCED. INT., 1986, 18, N 3, 206-209

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS
  申请人：Kandula Mahesh

  公开号：US20150133475A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I化合物的有效量的药物组合物，以及用于牙周炎和类风湿关节炎治疗的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。
• [EN] DISUBSTITUTED HETEROARYL-FUSED PYRIDINES<br/>[FR] PYRIDINES ACCOLÉES À DI-SUBSTITUTION HÉTÉROARYLE
  申请人：NOVARTIS AG

  公开号：WO2011076744A1

  公开（公告）日：2011-06-30

  The invention relates to compound of the formula (I') in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及公式(I')的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其作为药物的用途以及包含它的药物。
• DISUBSTITUTED HETEROARYL-FUSED PYRIDINES
  申请人：Babiger Sangamesh

  公开号：US20120258973A1

  公开（公告）日：2012-10-11

  The invention relates to compound of the formula (I′) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及式(I′)的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备，其作为药物的用途以及包含它的药物。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
  申请人：Cellix Bio Private Limited

  公开号：US20160120839A1

  公开（公告）日：2016-05-05

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

  该发明涉及公式I和公式II的化合物或其药用可接受盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。含有公式I或公式II化合物的有效量的药物组合物；以及治疗或预防炎症性肠病的方法可制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射。这些组合物可用于治疗胃肠疾病和炎症，如炎症性肠病、溃疡性结肠炎、轻度至中度克罗恩病、类风湿关节炎、炎症性关节炎、银屑病性关节炎、肝硬化和特发性荨麻疹。